National Osteoporosis Society's Position Statement on hormone replacement therapy in the prevention and treatment of osteoporosis

Menopause International

Volumn 17, Issue 2, 2011, Pages 63-65

  Bowring, C E ^a   Francis, R M ^a  

^a NATIONAL OSTEOPOROSIS SOCIETY   (United Kingdom)

Author keywords

fractures; HRT; menopause; Osteoporosis

Indexed keywords

CLINICAL EFFECTIVENESS; HEALTH CARE PERSONNEL; HEART DISEASE; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; MEDICAL SOCIETY; OSTEOPOROSIS; PATIENT SAFETY; PUBLICATION; REVIEW; RISK ASSESSMENT; SPINE FRACTURE; STROKE; VENOUS THROMBOEMBOLISM;

AGE FACTORS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; FEMALE; GREAT BRITAIN; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTORS; STROKE;

EID: 79959435269     PISSN: 17540453     EISSN: 17540461     Source Type: Journal    
DOI: 10.1258/mi.2011.011012     Document Type: Review

References (19)

1. Albright F, Smith PH, Richelson AM. Postmenopausal osteoporosis: its clinical features. JAMA 1941; 116: 2465–74
2. Richelson LS, Wahner HW, Melton LJ, Riggs BL. Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med 1984; 311: 1273–5
3. Aitken JM, Hart DM, Lindsay R. Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy. Br Med J 1973; iii: 515–518
4. Horsman A, Jones M, Francis R, Nordin C. The effect of estrogen dose on postmenopausal bone loss. N Engl J Med 1983; 309: 1405–7
5. Lindsay R, Tohme J. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol 1990; 76: 1–6
6. Lufkin EG, Wahner HW, O’Fallon WM,, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117: 1–9
7. Rossouw JE, Anderson GL, Prentice RL,, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–33
8. Cauley JA, Robbins J, Chen Z,, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003; 290: 1729–38
9. Anderson GL, Limacher M, Assaf AR,, et al. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–12
10. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419–27
11. Medicines and Healthcare Products Regulatory Agency/Committee on Safety of Medicines. Review of the evidence regarding long-term safety of HRT. Current Problems in Pharmacovigilance 2004; 30: 4–7
12. NICE. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. NICE Technology Appraisal 161, Amended January 2011
13. Shane E, Burr D, Ebeling PR,, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010; 25: 2267–94
14. Khosla S, Burr D, Cauley J,, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22: 1479–91
15. Santen RJ, Allred DC, Ardoin SP,, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010; 95: s1–s66
16. Studd J. Why are physicians reluctant to use estrogens for anything – or do they prefer ‘PROFOX’? Menopause Int 2009; 15: 52–54
17. Bowring C, Reid D, Francis R. Why are physicians reluctant to use estrogens for anything: or do they prefer ‘PROFOX’? Menopause Int 2009; 15:99
18. Studd J. Reply to letter from Dr Bowring et al. Menopause Int 2009; 15:99
19. National Osteoporosis Society. Hormone Replacement Therapy for the Treatment and Prevention of Osteoporosis, 2010. See http://www.nos.org.uk/document.doc?id=823 ( last checked 6 April 2011)